Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Delayed and precocious puberty in gynaecological practice
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Neurology, obstruction and safeguarding change urgency
Rapid early puberty with headache, vomiting, visual or focal neurological signs may reflect intracranial disease, while primary amenorrhoea with severe cyclical pain can reflect obstructed outflow; pregnancy or STI may signal abuse.
Action: Arrange urgent paediatric endocrine and neurological assessment for central signs, prompt adolescent-gynaecology imaging for suspected obstruction, and follow safeguarding procedures with private, trauma-informed communication when sexual harm is possible.
Overview
Recognise abnormal female pubertal timing, distinguish central from peripheral and gonadal from central failure, investigate primary amenorrhoea and anatomy, and coordinate age-appropriate endocrine treatment.
Puberty is a sequence, not a single event. In girls, breast development usually marks gonadal oestrogen action, pubic hair reflects adrenal androgen activity and menarche follows after further breast and uterine maturation. Timing varies by family, health and population, but specialist thresholds prevent important disease being dismissed. Breast development before 8 is precocious; no breast development by 13, no menarche by 15 or a gap exceeding three years after thelarche requires evaluation.
Central precocious puberty is early activation of pulsatile GnRH. Development is usually orderly: breasts progress, growth accelerates, bone age advances and the uterus becomes oestrogenised. It is commonly idiopathic in girls, but very young onset, neurological symptoms and rapid progression increase structural concern. Peripheral puberty comes from oestrogen or androgen outside central activation and can be incomplete or discordant. Ovarian cyst or tumour, adrenal disease, severe hypothyroidism, McCune-Albright syndrome and accidental exposure to household hormone gels are examples.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Localising delayed puberty
A 14-year-old has no breast development, short stature and a history of neonatal lymphoedema. Oestradiol is low and FSH is markedly raised. Which interpretation is most appropriate?
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Isolated premature thelarche causes breast tissue without sustained growth acceleration or other progression; premature adrenarche produces pubic hair or body odour without breast development. Neither should be labelled central puberty from one sign. Record serial height on a UK growth chart, calculate growth velocity, document Tanner stage and assess bone age. Progression over months, advanced skeletal maturation and a pubertal LH response make central activation more likely.
Delayed puberty can be constitutional, functional or permanent. Family history of late development and otherwise normal growth may support constitutional delay. Undernutrition, coeliac disease, inflammatory illness, renal disease, high exercise load and stress can suppress central signalling. Congenital GnRH deficiency may include anosmia. Pituitary tumour, surgery or irradiation can cause multiple deficits. High FSH with low oestradiol points to gonadal dysgenesis, Turner syndrome or ovarian injury from chemotherapy, radiotherapy or surgery.
Primary amenorrhoea requires anatomy as well as hormones. Normal breast development suggests meaningful oestrogen exposure. If the uterus is absent, distinguish Müllerian agenesis, in which ovaries and a 46,XX karyotype are typical, from complete androgen insensitivity, in which testes produce testosterone in a 46,XY individual but androgen action is absent. Each has different gonadal, renal, skeletal, genetic and fertility implications. If the uterus is present but cyclical pain occurs, inspect and image for imperforate hymen, transverse septum or other obstruction.
Initial tests are guided by development. Measure LH, FSH, oestradiol, TSH and free T4, prolactin and hCG when pregnancy is possible; add androgens and 17-hydroxyprogesterone for virilisation or isolated adrenarche. A left-hand and wrist radiograph estimates bone age. Pelvic ultrasound assesses uterus, endometrial effect and ovaries. BSPED's 2026 guidance uses GnRH or GnRH-agonist stimulation with assay-specific LH thresholds when basal findings do not settle central precocity.
Brain MRI is urgent for neurological signs and is commonly obtained in confirmed central precocity with very young onset or atypical rapid progression under paediatric endocrinology. Delayed puberty with other pituitary deficits, severe headache, visual change or diabetes-insipidus symptoms also needs MRI. Karyotype is important in hypergonadotrophic delayed puberty, short stature or suspected difference in sex development. Genetic testing should follow informed, age-appropriate counselling rather than surprise disclosure through an electronic result.
Treatment balances adult height, bone acquisition, uterine development and psychological wellbeing. Long-acting GnRH agonists suppress progressive central precocious puberty and are reviewed against growth, Tanner stage, bone age and biochemical suppression. Permanent hypogonadism needs pubertal induction at a physiologically low oestradiol dose, increased gradually so breast, uterine and skeletal development approximate normal tempo. Progestogen is introduced after adequate oestrogen exposure, usually after two to three years or significant breakthrough bleeding, when a uterus is present.
Key points
In girls, breast development before age 8 suggests precocious puberty; absent breast development by 13, no menarche by 15 or no menarche more than three years after thelarche requires assessment.
True central precocious puberty follows early hypothalamic-pituitary-gonadal activation with progressive breasts, growth acceleration and advanced bone age; isolated premature thelarche or adrenarche may not progress.
Peripheral puberty produces sex steroids independently of gonadotrophin activation and may be discordant, from ovarian or adrenal disease, severe hypothyroidism, McCune-Albright syndrome or exogenous hormones.
Plot serial height and growth velocity, document Tanner stage, family timing, nutrition, chronic disease, exercise, neurological symptoms and exposure to oestrogen or androgen products.
Bone age, basal LH and FSH with oestradiol, thyroid tests and pelvic ultrasound form the initial pattern; a specialist GnRH or GnRH-agonist stimulation test confirms uncertain central activation.
Delayed puberty with high FSH and low oestradiol indicates primary gonadal failure; low or normal gonadotrophins suggest constitutional delay, energy deficiency, chronic disease or hypothalamic-pituitary pathology.
Normal breast development with an absent uterus redirects primary-amenorrhoea assessment toward Müllerian agenesis or complete androgen insensitivity, requiring specialist anatomy, testosterone and genetic evaluation.
Aetiology
01
Early central activation
Idiopathic or structural hypothalamic GnRH activation begins the normal pubertal sequence before the expected age and advances skeletal maturation.
02
Peripheral sex-steroid exposure
Ovarian, adrenal, hCG, severe thyroid or exogenous hormone sources produce early development without initial central gonadotrophin activation.
03
Central pubertal delay
Constitutional timing, low energy, chronic disease or hypothalamic-pituitary pathology delays gonadotrophin secretion and ovarian oestrogen production.
04
Primary gonadal insufficiency
Turner syndrome, gonadal dysgenesis, chemotherapy, radiotherapy or surgery prevents adequate ovarian oestrogen and removes negative feedback.
Pathophysiology
1
GnRH pulsatility starts early
Central precocity activates LH and FSH, ovarian oestradiol, breast and uterine development, growth acceleration and bone-age advancement.
2
Peripheral hormones bypass control
Autonomous oestrogen or androgen acts on target tissues while basal and stimulated gonadotrophins remain suppressed until secondary activation sometimes follows.
3
Central signalling remains quiet
Constitutional, nutritional or organic hypothalamic-pituitary delay leaves oestradiol production and gonadotrophin stimulation low or inappropriately normal for age.
4
Gonadal feedback disappears
Ovarian failure reduces oestradiol and inhibin, allowing FSH to rise while breast, uterine and bone development remain inadequate.
Clinical features and red flags
Progressive central precocity
Breast progression, rapid linear growth, advanced bone age and oestrogenised uterine development before 8 form a coherent centrally activated sequence.
Peripheral discordance
Bleeding, breast or virilising signs without a pubertal gonadotrophin pattern suggest hormone production independent of the central axis.
Constitutional delay
Delayed but otherwise orderly growth and puberty with a family history of late timing and delayed bone age supports a benign tempo diagnosis after exclusion.
Primary gonadal failure
Absent or arrested breast development with low oestradiol and raised FSH indicates inadequate ovarian feedback and prompts Turner, genetic and iatrogenic assessment.
Anatomical amenorrhoea
Normal breast development with absent menarche, an absent uterus or cyclical obstructive pain requires a structured genital-anatomy and difference-of-sex-development pathway.
Red flags requiring action
Pubertal progression with headache, morning vomiting, visual change, seizures, focal neurological signs, polyuria or growth failure requires urgent central nervous system assessment.
Severe cyclical pelvic or abdominal pain, urinary retention or a pelvic mass with primary amenorrhoea suggests retained menstrual blood from outflow obstruction.
Rapid virilisation, clitoromegaly, voice deepening or markedly raised androgens suggests adrenal or gonadal disease rather than ordinary adrenarche.
Investigations
01Serial height, Tanner stage and bone ageFirst step
Why
Determine whether pubertal development is progressive and how sex-steroid exposure has altered skeletal maturation.
Interpretation and limitations
Growth acceleration and advanced bone age support progressive precocity; delayed bone age may fit constitutional or central delay, while Turner syndrome can combine short stature with less delay.
02LH, FSH and oestradiol
Why
Distinguish central activation, central delay and primary gonadal failure.
Interpretation and limitations
A pubertal LH pattern supports central precocity, high FSH with low oestradiol indicates ovarian failure and low gonadotrophins require nutritional, systemic and pituitary interpretation.
03GnRH or GnRH-agonist stimulation
Why
Confirm hypothalamic-pituitary-gonadal activation when basal hormones and progression are inconclusive.
Interpretation and limitations
Use BSPED's assay-specific stimulated LH thresholds with Tanner stage, growth, bone age and pelvic findings; the test is not interpreted from a universal number alone.
04Pelvic ultrasound
Why
Confirm uterine presence and oestrogen effect and assess ovarian volume, follicles, cyst or mass.
Interpretation and limitations
An enlarged pear-shaped uterus supports oestrogenisation, while absent uterus or ovarian mass redirects investigation; a simple cyst does not by itself prove persistent peripheral puberty.
Differential diagnosis
01
Premature thelarche
Isolated non-progressive breast tissue without accelerated growth, advanced bone age or other pubertal signs may be a benign variant.
02
Premature adrenarche
Pubic hair, body odour or mild acne without breast development reflects adrenal androgen and prompts virilisation-focused assessment if atypical.
03
Constitutional growth and puberty delay
Family late timing, delayed bone age and otherwise healthy slow maturation support a transient central delay after chronic disease is excluded.
04
Müllerian agenesis or androgen insensitivity
Normal breasts with absent uterus indicate an anatomical or sex-development difference rather than absent oestrogen, requiring gonadal and genetic distinction.
05
Outflow obstruction
A present functioning uterus behind an imperforate hymen or transverse septum causes primary amenorrhoea with cyclical pain and retained blood.
Management
01Early developmentSeparate progression from a benign variantFirst stepBreast, pubic hair or bleeding occurs before the expected age.+
1Plot serial growth, stage breasts and pubic hair, ask about neurological symptoms and exogenous hormones and examine for café-au-lait lesions or virilisation.
2Obtain bone age, basal gonadotrophins with oestradiol and pelvic ultrasound, adding thyroid, adrenal or hCG testing from the specific pattern.
3Use specialist stimulation testing and risk-based MRI to distinguish central activation, isolated thelarche or adrenarche and peripheral hormone production.
02Delayed developmentLocalise gonadal versus central delayBreast development is absent by 13, progression has arrested or menarche has not occurred by 15.+
1Review growth, family timing, nutrition, exercise, chronic disease, anosmia, previous cancer therapy, medicines and psychosocial wellbeing.
Complications
01
Reduced adult height
Untreated progressive precocity advances epiphyseal maturation, initially making a child tall but shortening the remaining growth window.
02
Low peak bone mass
Delayed or absent oestrogen exposure impairs adolescent bone acquisition, especially when nutrition, inflammation or glucocorticoids add risk.
03
Obstructed menstrual retention
An outflow block can cause haematocolpos, pain, urinary retention, infection and endometriosis if functioning endometrium remains trapped.
04
Psychosocial and safeguarding harm
Being developmentally out of step can cause distress and bullying, while sexual abuse or exploitation may be overlooked without private assessment.
Monitoring and follow-up
Measure height, growth velocity, blood pressure and Tanner stage about every six months, with bone age usually yearly during active induction or suppression.
During GnRH-agonist treatment, check for continued breast progression or bleeding and use specialist biochemical stimulation only when clinical suppression is uncertain.
During oestrogen induction, increase dose from growth and pubertal response rather than rushing to an adult combined pill, and assess uterine development before full replacement.
Review bone health, nutrition, chronic disease, mental health, school and peer effects throughout treatment, not only laboratory targets.
Plan transition to adult endocrinology, gynaecology, genetics and fertility care with the diagnosis, anatomy, hormone regimen and surveillance needs clearly documented.
Special situations
Adrenarche is not gonadarche
Pubic hair and body odour can arise from adrenal androgen without breast development or central ovarian-axis activation.
Tempo gives diagnostic power
Serial progression, growth velocity and bone-age advancement distinguish active precocity more reliably than a single borderline hormone result.
Normal breasts localise function
Established breast development demonstrates oestrogen effect and makes uterine anatomy central to investigation of primary amenorrhoea.
High-dose oestrogen can cost height
Rapid early escalation advances epiphyseal maturation and may compromise final height and breast or uterine development, so induction mimics normal tempo.
The diagnosis outlives paediatrics
Turner syndrome, DSD, pituitary disease and permanent hypogonadism require deliberate adult transition for cardiovascular, bone, sexual and fertility care.
Common pitfalls
01
Calling isolated pubic hair central precocious puberty without breast development, growth acceleration or axis testing.
02
Reassuring early rapid progression despite headache, visual change or advanced bone age.
03
Waiting beyond age 15 to investigate absent menarche or overlooking the earlier absent-breast threshold at 13.
04
Ordering hormone tests without plotting serial height, growth velocity and pubertal stage.
05
Assuming normal breast development means the uterus and outflow tract must be normal.
06
Starting an adult-dose combined pill for pubertal induction instead of gradually escalating physiological oestradiol.
Progressive central precocious puberty can be paused with a long-acting GnRH agonist; permanent hypogonadism is treated with low-dose oestradiol increased gradually over about two to three years, adding progestogen later when a uterus is present.
Pregnancy, genital injury, sexually transmitted infection or sexualised behaviour inconsistent with development requires sensitive safeguarding assessment and statutory escalation where indicated.
Short stature with hypertension, cardiac findings, webbed neck or absent breast development raises Turner syndrome and needs prompt cardiovascular as well as endocrine assessment.
05Thyroid, prolactin, hCG and androgen tests
Why
Identify endocrine, pregnancy and adrenal or gonadal alternatives selected from the phenotype.
Interpretation and limitations
Severe hypothyroidism can paradoxically cause early bleeding; raised hCG or marked androgen results require urgent cause-specific and safeguarding-aware assessment.
06MRI and genetic analysis
Why
Investigate central nervous system disease, gonadal dysgenesis or a difference in sex development when the pattern supports it.
Interpretation and limitations
Neurological signs accelerate MRI; karyotype and targeted genetics require counselling and change cardiac, gonadal, renal, fertility and family care.
2
Measure gonadotrophins with oestradiol, thyroid and prolactin and use bone age to distinguish hypergonadotrophic from central or constitutional patterns.
3Arrange karyotype, pituitary imaging or disease-specific tests when phenotype or hormones support Turner, gonadal dysgenesis or organic central disease.
03Primary amenorrhoeaConfirm uterus, outflow and gonadal contextMenarche has not occurred despite breast development or cyclical symptoms.+
1EscalationUse consented examination and ultrasound to confirm uterus, vagina and any retained blood, escalating painful obstruction promptly.
2If uterus is absent, assess testosterone, gonads, karyotype and associated renal or skeletal features through adolescent gynaecology and DSD expertise.
3Provide staged disclosure, psychological support and fertility information appropriate to age, capacity and the confirmed diagnosis.
04TreatmentMatch suppression or induction to mechanismProgressive central precocity or permanent hypogonadism has been confirmed.+
1Use a licensed long-acting GnRH agonist for progressive central precocity when height or psychosocial benefit justifies treatment, monitoring suppression and growth.
2For permanent deficiency, start low-dose 17β-oestradiol and increase over about two to three years according to growth and breast and uterine development.
3Add cyclic progestogen after adequate oestrogen exposure or significant breakthrough bleeding when a uterus is present, then transition to adult replacement care.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
Sustained GnRH-receptor stimulation suppresses gonadotrophins after an initial flare, pausing progressive central pubertal development and bone-age advancement.
Triptorelin depot
For licensed central precocious puberty, one option is triptorelin 22.5 mg by deep intramuscular injection every 24 weeks; formulation and interval are selected by paediatric endocrinology.
Confirm central rather than peripheral puberty, exclude pregnancy where relevant, give injections on time and monitor growth, bone age, pubertal signs, initial vaginal bleeding, mood and injection reactions.
Mimics gradual physiological puberty in permanent ovarian or central hypogonadism while supporting breast, uterine, growth and bone development.
Low-dose transdermal 17β-oestradiol
A BSPED specialist regimen may begin with one-quarter of a 25 microgram/24-hour matrix patch for 3–4 days followed by 3–4 patch-free days, escalating about every six months.
Patch cutting and paediatric use require specialist product selection and instruction; increase slowly, monitor growth and blood pressure, and add progestogen later when a uterus is present.
Protects the oestrogen-exposed endometrium and produces controlled withdrawal bleeding after pubertal induction in a patient with a uterus.
Cyclic micronised progesterone
After adequate oestrogen exposure, give 200 mg orally at night for at least 12 days every one to three months, then move toward a regular adult cycle regimen.
Do not introduce too early without a reason because uterine maturation may be incomplete; review sedation, adherence and unexpected heavy or persistent bleeding.